Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | PRKACA | P17612 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27607302 | 0.96 | HDAC4 (0.51) | SCN9AHDAC4RAB9AMEN1KMT2A | |
| SCHEMBL14564377 | 0.86 | SCN9A (0.62) | SCN9AHDAC4IMPDH2 | |
| SCHEMBL16159514 | 0.85 | HDAC4 (0.45) | SCN9AHDAC4RAB9AMEN1KMT2A | |
| SCHEMBL16159726 | 0.81 | HDAC4 (0.44) | SCN9AHDAC4IMPDH2EDNRBEDNRA | |
| SCHEMBL16159513 | 0.81 | SCN9A (0.46) | SCN9AHDAC4IMPDH2EDNRBEDNRA | |
| SCHEMBL1646144 | 0.81 | ALDH1A1 (0.50) | HDAC4RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL16159199 | 0.80 | HDAC4 (0.43) | SCN9AHDAC4IMPDH2EDNRBEDNRA | |
| SCHEMBL16159200 | 0.80 | SCN9A (0.45) | SCN9AHDAC4IMPDH2EDNRBEDNRA | |
| SCHEMBL3193030 | 0.79 | LMNA (0.43) | SCN9AHDAC4RAB9ANPC1ADORA2A | |
| SCHEMBL16159201 | 0.79 | SCN9A (0.45) | SCN9AHDAC4IMPDH2EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 880 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040505-A | Phosphorus phenol ligand, phosphorus phenol complex, preparation method and application thereof, and ethylene polymerization method | 南开大学 | 2025-05-27 | — | — | CN | claimed |
| CN-114920719-A | Preparation method of 3-furfural | 湖南华腾制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| EP-3019477-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-05-26 | — | — | EP | claimed |
| CN-107011336-A | One class is using pyridine as the pH fluorescence probes and its application for protonating site | 同济大学 | 2017-08-04 | — | — | CN | claimed |
| US-9714224-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-07-25 | — | — | US | claimed |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2016-05-26 | — | — | US | claimed |
| EP-3019477-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | Novartis AG (CH) | 2016-05-18 | — | — | EP | claimed |
| WO-2015003223-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-01-15 | — | — | WO | claimed |
| EP-0699192-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-03-06 | — | — | EP | claimed |
| WO-1994027980-A1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1994-12-08 | — | — | WO | claimed |
| US-5142545-A | LASER DYE | LAMBDA PHYSIK GESELLSCHAFT ZUR HERSTELLUNG VON LASERN MBH (DE) | 1992-08-25 | — | — | US | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
| US-4891305-A | LASERS | RICOH CO., LTD. (JP) | 1990-01-02 | — | — | US | claimed |
| US-4102688-A | CONTAINING PYRAZOLO(3,4-B)PYRIDINE/3,6-DIONE MOIETY | FUJI PHOTO FILM CO., LTD. (JP) | 1978-07-25 | — | — | US | claimed |
| US-3977880-A | Direct-positive emulsion containing silver halide grains internally doped with metal ions, surface ripened with gold and sulfur compound and fogged by light exposure | FUJI PHOTO FILM CO., LTD. (JA) | 1976-08-31 | — | — | US | claimed |
| US-3970461-A | Fogged, direct-positive silver halide emulsion containing carbocyanine dye having indolenine nucleus | FUJI PHOTO FILM CO., LTD. (JA) | 1976-07-20 | — | — | US | claimed |
| EP-4725942-A1 | COMPOUNDS ACTIVE ON CYCLIN D1 PATHWAY AND THEIR USE | Sibylla Biotech S.p.A. (IT) | 2026-04-15 | — | — | EP | disclosed |
| US-12595244-B2 | Small molecule inhibitors of mammalian SLC6A19 function | JNANA THERAPEUTICS INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-3935010-A | IMIDAZOQUINOXALINE DESENSITIZER | EASTMAN KODAK COMPANY (US) | 1976-01-27 | — | — | US | disclosed |
| US-3933507-A | LIGHT INSENSITIVE SILVER SALT, POLYMETHINE SENSITIZER | AGFA-GEVAERT, A.G. (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595244-B2 | Small molecule inhibitors of mammalian SLC6A19 function | SLC6A19, SLC6A15, SLC19A1 | SCN9A 125/4885HDAC4 2129/4885RAB9A 747/4885 |
| US-20160145213-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, AGT | SCN9A 4177/4885HDAC4 2572/4885RAB9A 3785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.